Cangrelor vs Ticagrelor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: P2Y12 receptor · full Atherosclerotic Cardiovascular Disease pipeline

Cangrelor · Kengreal

Marketed by Chiesi Farmaceutici

Approved in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT01156571 · Phase 3 · completed

This was a large randomized, quadruple-blind, active-controlled trial with a hard, adjudicated clinical primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR) (randomization through 48 hours post randomization): Death, MI or ischemia-driven revascularization at 48 h: 7.0% cangrelor (185/2654) vs 8.0% placebo (210/2641); OR 0.87, 95% CI 0.71 to 1.07; P=0.17. Both arms received clopidogrel 600 mg (CHAMPION PLATFORM, NEJM 2009). (missed)

Result source: NCT00385138

Ticagrelor · Brilinta

Marketed by AstraZeneca

Approved in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT01732822 · Phase 3 · completed

This was a large, randomized, quadruple-blind, active-controlled trial of 13,885 participants, using cardiovascular death, myocardial infarction, or ischemic stroke as a hard clinical primary endpoint. The primary comparison was not statistically significant: 751 events with ticagrelor versus 740 with clopidogrel (hazard ratio 1.02, 95% CI 0.92–1.13; p=0.650), so the results provide well-controlled but inconclusive evidence for ticagrelor's benefit in this population.

Next expected readout: December 2026 · NCT04937699 (registry estimate)

Reported efficacy

Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke (From randomization to PACD, an average of 2.5 years): Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke (From randomization to PACD, an average of 2.5 years): Ticagrelor 90 mg bd 751 Participants | Clopidogrel 75 mg od 740 Participants (missed)

Result source: NCT01732822

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCangrelorTicagrelor
LDL-C, % change—Not reported—Trial running · NCT03789916
Non-HDL-C, % change—Not reported—Trial running · NCT03789916
ApoB, % change—Not reported—Trial running · NCT03789916
Lp(a), % change—Not reported—Trial running · NCT03789916
3-point MACE (% with event)—Not reported—Trial running · NCT03789916

LDL-C, % change

Cangrelor
—Not reported
Ticagrelor
—Trial running · NCT03789916

Non-HDL-C, % change

Cangrelor
—Not reported
Ticagrelor
—Trial running · NCT03789916

ApoB, % change

Cangrelor
—Not reported
Ticagrelor
—Trial running · NCT03789916

Lp(a), % change

Cangrelor
—Not reported
Ticagrelor
—Trial running · NCT03789916

3-point MACE (% with event)

Cangrelor
—Not reported
Ticagrelor
—Trial running · NCT03789916
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ticagrelor: registry results are on file for Atherosclerotic Cardiovascular Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cangrelor: 3 of 4 rows · Ticagrelor: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCangrelor
Dropout rate
0.3%a
NCT01156571 · Phase 3 · combination
show 1 more result
1.1%
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Discontinued due to AEs
—a
NCT01156571 · Phase 3 · combination
show 1 more result
—
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Serious AEs
2.2%a
NCT01156571 · Phase 3 · combination
show 1 more result
1.8%
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Most frequent reported AEs
a
back pain 3.4%
chest pain 2.7%
nausea 2.7%
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cangrelor

All-cause Mortality MI IDR Composite 7% (n=2654) vs 8% (n=2641) Clopidogrel @ 0.29wk
event count · % of participants
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 185 participants as posted
show 1 more result
8.6% (n=2647) vs 9.5% (n=2629) Clopidogrel @ 4.29wk*
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 227 participants as posted
All-cause Mortality or MI Composite 6.8% (n=2654) vs 7.7% (n=2641) Clopidogrel @ 0.29wk
event count · % of participants
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 180 participants as posted
show 1 more result
8% (n=2647) vs 8.9% (n=2629) Clopidogrel @ 4.29wk*
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 213 participants as posted
MI 6.7% (n=2654) vs 7.2% (n=2641) Clopidogrel @ 0.29wk
event count · % of participants
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 177 participants as posted
show 1 more result
7.1% (n=2647) vs 7.6% (n=2629) Clopidogrel @ 4.29wk*
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 189 participants as posted
IDR 0.7% (n=2654) vs 0.9% (n=2641) Clopidogrel @ 0.29wk
event count · % of participants
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 19 participants as posted
show 1 more result
1.4% (n=2647) vs 1.7% (n=2629) Clopidogrel @ 4.29wk*
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 37 participants as posted
Stent Thrombosis 0.2% (n=2654) vs 0.6% (n=2641) Clopidogrel @ 0.29wk
event count · % of participants
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 5 participants as posted
show 1 more result
0.6% (n=2647) vs 1.1% (n=2629) Clopidogrel @ 4.29wk*
NCT00385138 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 · converted to % from 15 participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cangrelor's landscape · Ticagrelor's landscape